Category:Other Chemotherapy and Cancer Drugs

From Glioblastoma Treatments
Revision as of 06:14, 24 March 2024 by Lazy (talk | contribs) (Created page with "Category:Other Chemotherapy and Cancer DrugsThis category encompasses a range of chemotherapy and cancer drugs used in the treatment of glioblastoma and other high-grade gliomas. These treatments are integral to multimodal cancer therapy approaches, combining traditional chemotherapy agents with newer, targeted drugs to improve patient outcomes.List of TreatmentsHere we provide an overview of various chemotherapy and cancer drugs categorized under "Other Chemotherapy and...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

Category:Other Chemotherapy and Cancer DrugsThis category encompasses a range of chemotherapy and cancer drugs used in the treatment of glioblastoma and other high-grade gliomas. These treatments are integral to multimodal cancer therapy approaches, combining traditional chemotherapy agents with newer, targeted drugs to improve patient outcomes.List of TreatmentsHere we provide an overview of various chemotherapy and cancer drugs categorized under "Other Chemotherapy and Cancer Drugs." These treatments have been utilized in clinical trials and have shown varying degrees of efficacy in the management of glioblastoma multiforme (GBM) and other malignancies.

 Has treatment nameHas clinical trial phaseHas common side effectsHas OS withHas usefulness rating
BCNU (Carmustine) and Gliadel (Carmustine Wafers)BCNU (Carmustine) and Gliadel (Carmustine Wafers)Phase III (Europe for Gliadel)Low blood counts, pulmonary problems, infection, and seizures for GliadelGliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months
Bevacizumab (Avastin)Bevacizumab (Avastin)Phase IIIHypertension, proteinuria, and hemorrhageAVAglio trial: 16.8 months; RTOG trial: 15.7 months
CCNU (Lomustine)CCNU (Lomustine)Phase 3 (Germany)Hematological toxicity, nausea, vomiting, and pulmonary toxicity23 months median survival, with 47% at 2 years
Gleevec (Imatinib)Gleevec (Imatinib)Exploratory/Investigational (Specific phase for gliomas not provided)Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population.Not applicable; studies focusing on PFS-6 as a primary endpoint
Platinum CompoundsPlatinum CompoundsVarious, including Phase IINephrotoxicity, ototoxicity, and neurotoxicityNot specified
ProcarbazineProcarbazineNot specifiedHematological toxicity, nausea, and neurological effectsNot specified

Pages in category "Other Chemotherapy and Cancer Drugs"

The following 6 pages are in this category, out of 6 total.